Immunology

NEWS: Today we announced topline results from our Phase 3 study in #AlopeciaAreata. Learn how this study underscores our commitment to improving the lives of people living with immune-mediated diseases where the burden of disease is significant and treatment options remain limited. Read more: https://bit.ly/4mEajHZ #immunology [Video description: On-screen text reads, “Immunology News”]

JUST IN: We’ve signed a definitive agreement to acquire Capstan Therapeutics. This agreement underscores our commitment to drive scientific innovation and transform patient care in #immunology. Learn more: https://bit.ly/44Gi8X9 [Video description: On-screen text reads, "Immunology News."]

At #EULAR2025, we're excited to collaborate with Global Remission Coalition and health care providers to advance the conversation around remission as a treatment goal in inflammatory #RheumaticDisease. Achieving remission delivers value far beyond symptom relief – creating measurable benefits for patients, providers and health systems globally. Learn more below. ⬇

At #EULAR2025, we’re presenting 24 abstracts featuring data across our #rheumatology portfolio. Explore our commitment to immunology: https://bit.ly/4mVzExG [Video description: Icons depicting various profiles. On-screen text reads, “EULAR 2025 Looking ahead. 24 accepted abstracts across 5 rheumatic diseases, axial spondyloarthritis, giant cell arteritis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus. See you there.”]

Recently, we brought together individuals living with #IBD to share their journeys. Their stories highlighted one consistent theme: the importance of strong doctor-patient relationships in managing IBD effectively. When patients feel heard and health care providers truly understand their unique experiences, there is potential for improved treatment outcomes. By creating spaces for these important conversations and amplifying patient voices, we're committed to supporting the IBD community every day. #WorldIBDDay [Video description: Sina, an IBD patient from Germany, shares what’s important in the doctor-patient relationship.]

Millions of people globally live with #axSpA, a chronic inflammatory disease that causes pain and stiffness in the spine and hips. As #WorldASDay approaches, this year’s #LaceUpForAxSpA theme encourages a deeper understanding of axSpA symptoms and daily challenges. At AbbVie, we are committed to raising awareness of axSpA and related conditions. Learn more from Axial Spondyloarthritis International Federation: https://bit.ly/3RKq3vq [Video description: Animation of people with orange shirts and different shoes. On-screen text reads, “Axial spondyloarthritis (axSpA) is a chronic inflammatory disease affecting millions worldwide. Pain and stiffness in the spine and hips make simple tasks more challenging, like tying your shoelaces. Unlike many conditions, axSpA symptoms worsen with inactivity. Regular movement is an important part of disease management. Many people wait years for a correct diagnosis. Early detection leads to better outcomes. Learn more about axSpA and help raise awareness today.“]

JUST IN: The European Medicines Agency approved our treatment for adults with #GiantCellArteritis, a #Rheumatic autoimmune disease. To learn more, click here: https://bit.ly/4cyfLYT [Video description: On-screen text reads, “Immunology News.”]

NEWS: Andy Anisfeld and Chudi Nduaka highlight our presence at #AAD2025 and reiterate our commitment to redefining treatment expectations for people living with chronic inflammatory skin conditions.   [Image description: Andrew Anisfeld, Ph,D., VP, Global Medical Affairs, Immunology, says, “AbbVie's presence at AAD this year highlights our commitment to elevating dermatological care through innovative treatment solutions.” Chudi Nduaka, Therapeutic Head, Dermatology Medical Affairs, says, “We look forward to continuing our work in improving outcomes for patients living with chronic inflammatory skin conditions.”]

NEWS: The European Medicines Agency's #CHMP granted a positive opinion for our investigational treatment of #GiantCellArteritis in adults. Read more: https://bit.ly/4bk7EyA #GCA [Video description: On-screen text reads, “Immunology News.”]